We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia—Reply

Peter B. Jones, MD, PhD; Thomas R. E. Barnes, MD, DSc; Peter Elton, DPH; Linda Davies, MSc; Graham Dunn, PhD; Helen Lloyd, BA; Karen P. Hayhurst, MSc; Robin M. Murray, MD, DSc; Alison Marwick, BA; Shôn Lewis, MD
Arch Gen Psychiatry. 2007;64(8):979-980. doi:10.1001/archpsyc.64.8.979.
Text Size: A A A
Published online


In reply

We are grateful to the correspondents for their careful consideration of data from CUtLASS 1,1 and for making comparisons with CATIE and other major trials.

The characteristics of sulpiride and the use of depot drugs, mentioned by Andrade and Kharawala, were discussed in our article and we have nothing to add; sulpiride would have had to have been more atypical than the atypical antipsychotics to have accounted for our results. Mintz and Kopelowicz concentrate on all-cause discontinuations and switching between FGAs and SGAs. They identify evidence to support superiority of olanzapine over FGAs. This would be a reasonable hypothesis to test in a study designed for this purpose. However, we point out that all-cause discontinuation was neither a primary nor a secondary outcome in our study. The data were presented to show patient flows according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines but will give a misguided view on this important question.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.